BlackRock Portfolio holdings
BlackRock, Inc., founded in 1988 by Larry Fink and a group of partners, is the world’s largest asset management firm, headquartered in New York City. Initially starting as a risk management and fixed-income institutional asset manager, it has grown to manage over $10 trillion in assets through a combination of organic growth and strategic acquisitions, such as its 2009 purchase of Barclays Global Investors. BlackRock is known for its extensive range of investment products, including mutual funds, ETFs (notably under the iShares brand), and alternative investments, serving clients ranging from individuals to governments.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Palantir
PLTR
|
+$926M |
| 2 |
Sea Limited
SE
|
+$712M |
| 3 |
iShares Core MSCI Total International Stock ETF
IXUS
|
+$697M |
| 4 |
Wells Fargo
WFC
|
+$687M |
| 5 |
Blackstone
BX
|
+$652M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$16.4B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.4B |
| 3 |
Apple
AAPL
|
+$3.41B |
| 4 |
Microsoft
MSFT
|
+$3.3B |
| 5 |
Linde
LIN
|
+$2.07B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.52% |
| 2 | Healthcare | 13.51% |
| 3 | Financials | 13.07% |
| 4 | Consumer Discretionary | 11.27% |
| 5 | Communication Services | 8.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3151
CuriosityStream
CURI
$156M
| $24.9M | ﹤0.01% |
1,826,462
+1,423,721
| +354% | +$18.4M |
|
3152
iShares Bloomberg Roll Select Commodity Strategy ETF
CMDY
$549M
| $24.8M | ﹤0.01% |
+450,465
| New | +$23.8M |
|
3153
Spero Therapeutics
SPRO
$71.2M
| $24.8M | ﹤0.01% |
1,778,822
+2,226
| +0.1% | +$31.1K |
|
3154
Lifecore Biomedical
LFCR
$163M
| $24.8M | ﹤0.01% |
2,205,409
+22,251
| +1% | +$256K |
|
3155
Eos Energy Enterprises
EOSE
$1.57B
| $24.7M | ﹤0.01% |
1,377,476
+685,253
| +99% | +$11M |
|
3156
SIGA Technologies
SIGA
$232M
| $24.7M | ﹤0.01% |
3,932,906
-755,535
| -16% | -$5.19M |
|
3157
Sun Life Financial
SLF
$45.6B
| $24.7M | ﹤0.01% |
479,224
-5,261
| -1% | -$278K |
|
3158
RBB Bancorp
RBB
$455M
| $24.7M | ﹤0.01% |
1,018,590
-231,452
| -19% | -$5.18M |
|
3159
State Street Materials Select Sector SPDR ETF
XLB
$8.52B
| $24.6M | ﹤0.01% |
598,352
-46,672
| -7% | -$1.97M |
|
|
XONE
3160
DELISTED
The ExOne Company
XONE
| $24.6M | ﹤0.01% |
1,136,873
+113,783
| +11% | +$2.59M |
|
|
BCEL
3161
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $24.5M | ﹤0.01% |
2,875,550
+461,015
| +19% | +$4.72M |
|
3162
CGI
GIB
$15.4B
| $24.5M | ﹤0.01% |
270,019
+16,525
| +7% | +$1.46M |
|
3163
Afya
AFYA
$1.27B
| $24.4M | ﹤0.01% |
948,330
+6,390
| +0.7% | +$150K |
|
3164
Neuronetics
STIM
$160M
| $24.4M | ﹤0.01% |
1,525,977
+1,098,612
| +257% | +$15.2M |
|
3165
CALL
Liberty Global Class A
LBTYA
$3.72B
| $24.4M | ﹤0.01% |
900,000
| – | – |
|
3166
CEL-SCI Corp
CVM
$23.8M
| $24.4M | ﹤0.01% |
93,793
+7,521
| +9% | +$4.65M |
|
3167
Q32 Bio
QTTB
$480M
| $24.4M | ﹤0.01% |
186,563
+27,389
| +17% | +$3.42M |
|
|
RBNC
3168
DELISTED
Reliant Bancorp, Inc. Common Stock
RBNC
| $24.4M | ﹤0.01% |
878,464
-51,589
| -6% | -$1.48M |
|
3169
Neurogene
NGNE
$686M
| $24.4M | ﹤0.01% |
131,938
-3,553
| -3% | -$786K |
|
3170
Lineage Cell Therapeutics
LCTX
$279M
| $24.3M | ﹤0.01% |
8,539,530
+6,076,041
| +247% | +$15.7M |
|
|
SYRS
3171
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $24.3M | ﹤0.01% |
446,336
+29,540
| +7% | +$1.75M |
|
3172
Cullinan Oncology
CGEM
$1.08B
| $24.3M | ﹤0.01% |
942,278
+54,470
| +6% | +$1.68M |
|
|
CSLT
3173
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $24.3M | ﹤0.01% |
9,223,966
+6,032,873
| +189% | +$11.2M |
|
3174
iShares Global REIT ETF
REET
$5.12B
| $24.2M | ﹤0.01% |
873,286
-35,288
| -4% | -$964K |
|
3175
Transcat
TRNS
$860M
| $24.1M | ﹤0.01% |
426,872
+10,713
| +3% | +$558K |
|
Similar funds
BlackRock's Q2 2021 Portfolio in Review
As of Q2 2021, BlackRock held 5,668 positions worth $3.59T, up 5.6% from $3.4T the previous quarter. Its ten largest holdings account for 18% of the portfolio.
BlackRock's Q2 2021 filing shows 333 new, 2,001 increased, 2,748 reduced and 150 closed positions. Its largest new stake was Organon & Co: 16,503,495 shares worth $499M. The largest sale was Alibaba, an estimated $16.4B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.
- BlackRock's largest Q2 2021 buy was Organon & Co: 16,503,495 shares worth $499M.
- BlackRock added most to Palantir in Q2 2021, an estimated $926M increase.
- BlackRock's biggest Q2 2021 reduction was Alibaba, cutting an estimated $16.4B.
- BlackRock fully exited Varian Medical Systems, Inc. in Q2 2021, selling an estimated $1.35B.
- BlackRock's ten largest holdings make up 18% of its $3.59T portfolio in Q2 2021.
- BlackRock opened 333 new positions and closed 150 in Q2 2021.
- BlackRock's portfolio value rose 5.6% quarter-over-quarter to $3.59T.
Based on BlackRock's 13F filing for Q2 2021, filed 11 Aug 2021.